Abstract: The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted aryl or heteroaryl; R is an H or, when formed with R1, a 5- or 6-member ring fused with an aryl or heretoaryl group optionally containing one or more of O, S, N, NH, and Nalk, being optionally substituted; R2 and R3 are, independently, an H, Hal, or alkyl optionally substituted by one or more Hal; R4 is H; and R5 is an H or alkyl optionally substituted by one or more halogen atoms. Said materials being in any isomeric form and the salts thereof, and are intended for drugs, particularly AKT(PKB) phosphorylation inhibitors.

Abstract: In an implantable medical device, such as a cardiac stimulator such as a pacemaker, and method for predicting patient responses to physical exertion, the patient response is monitored over time to evaluate disease progression and pacing therapies of cardiac stimulators are adapted based on the predicted patient response. A current cardiac status indicator for the patient is created indicating a response of the patient to an increased physical activity as a primarily heart rate response or as a primarily a stroke volume response. The pacing parameters of the cardiac stimulator can thereafter be adapted depending on the current cardiac status indicator, wherein the adapted pacing parameters include a first pacing setting if the current cardiac status indicator indicates a primarily heart rate response or a second pacing setting if the current cardiac status indicator indicates a primarily stroke volume response.

Abstract: The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted L-aryl or L-heteroaryl, such that L is a single bond, alkyl, CO, or CO-alk, or L-X, with L? being an alkyl and X being O or S; R2 is H or alkyl; R3 is an alkyl optionally substituted by Hal; and R4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.

Abstract: The invention relates to the novel products of formula (I): in which Z represents —O—, —NH or Nalk; n represents 0 to 4; R1 represents Hal, hydroxyl, alkyl or alkoxy; the alkyl and alkoxy radicals being optionally substituted; R2 and R3 represent H, Hal or alkyl optionally substituted with one or more halogen atoms; R4 represents H; these products being in all the isomer forms and the salts, as medicaments, in particular as inhibitors of AKT(PKB) phosphorylation.

Abstract: An implantable medical device is connectable to at least three electrodes, and includes an immittance measurer that performs immittance measurements within the heart of a patient using at least three electrodes coupled to the device, with at least one of the electrodes is arranged in an atrium of the patient's heart. The medical device further includes an immittance converter that converts the immittance measurement values into individual near-field immittance values of the at least one electrode arranged in an atrium, an atrial dilatation detector that detects atrial dilatation based upon the individual near-field immittance values, and that determines atrial dilatation values in dependence thereon, and an atrial fibrillation risk determiner that determines an atrial fibrillation risk index based upon the atrial dilatation values.

Abstract: The invention relates to the novel materials of formula (I), where R1 is an optionally substituted L-aryl or -heteroaryl, such that L is: an alkyl or CO, or LX, with Lbeing an alkyl and X being O or S; R2 is H or an alkyl; R3 is an alkyl optionally substituted by Hal; and R4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.

Abstract: An implantable medical device applies an electric signal over two electrodes and measures the resulting electric signal over a candidate pair of neighboring electrodes on a lead for a first heart ventricle or over a candidate electrode of the lead and a case electrode. An impedance signal is determined for each candidate pair or electrode based on the applied signal and the measured resulting signal. A time difference between start of contraction in a second ventricle and the timing of local myocardial contraction as identified from the impedance signal at the site of the candidate pair or electrode is determined for each candidate pair or electrode. An optimal pacing electrode is selected to correspond to one of the electrodes of the candidate pair having the largest time difference or the candidate electrode having largest time difference.

Abstract: The present invention relates to compounds of formula I, to the preparation thereof and to the therapeutic use thereof.

Abstract: A burner for a gas turbine including a burner housing is provided. Provided is a lean-rich partially premixed low emission burner for a gas turbine combustor providing stable ignition and combustion process at all engine load conditions. At the upstream end of that burner a pilot combustor creates a flow of an unquenched concentration of radicals and heat. Respectively provided is a plurality of quarl sections surrounding the exit of the pilot combustor, a main combustion room defined downstream the pilot combustor and at least a first channel defined as an annular space between an upstream quarl section and the closest downstream quarl section providing air and fuel to a main flame in the combustion room.

Abstract: The present invention relates to derivatives of 1,2,3,4-tetrahydropyrrolo-[1,2-a]pyrazine-6-carboxamides and of 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]diazepine-7-carboxamides, to the preparation thereof and to the therapeutic use thereof.

Abstract: The present invention relates to derivatives of 1-oxo-isoindoline-4-carboxamides and of 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamides, to the preparation thereof and to the therapeutic use thereof.

Abstract: The present invention relates to derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 1-oxo-3,4-dihydroquinazoline-8-carboxamides, to the preparation thereof and to the therapeutic use thereof.

Abstract: The present invention relates to the segmentation of two-dimensional gel electrophoresis images (2D images). The method according to the invention associates an initial protein seed candidate with an interface circumscribing said seed and thereafter brings said interface to evolve in accordance with a defined speed function F(x, y). The evolution of the interface is halted by a stopping criterion, C. According to the invention, the speed function can depend on a wide variety of parameters such as the pixel intensity, the curvature of the pixel intensity, the distance to the initial seed, the curvature and/or shape and/or normal direction and/or position of the evolving interface. The stopping criterion depends e.g. on the speed function F and/or the time of arrival T(x, y) and/or the departure time Td for said interface. The invention provides criteria for a specific treatment of saturated spots and to mike sure that interfaces never overlap.